A few things are worth keeping in mind when talking specifically about Faron. It is a drug development company. No revenue, no product, no business operations. The drug candidate has a certain potential, which of course has its own value, but Faron’s value is currently speculative. It is not mathematical in any respect. There is no revenue, so there is no calculable valuation. And here is my most important point regarding this: Speculative value cannot be expected to develop in a steadily upward trend, as is the case with a normal revenue-generating company. A normal company’s valuation rises when earnings improve or are expected to improve by x percent. Faron does not have these expectations in the same way. With Faron, the expectation is whether the drug succeeds or not. Almost all components of value formation are based on speculation.
In my opinion, Juho has been a good CEO. The trials have progressed almost as reported so far. Now the FDA threw a curveball (the dose-finding requirement), but that is not Juho’s fault. That FDA curveball could also be the reason why partnering did not succeed at the end of the year. We don’t know that. Currently, it’s quiet on the news front, but that’s perfectly understandable if there’s nothing to report. I also own unlisted companies, and in their case, years can go by where the only announcements are once a year at the AGM. Pointless press releases don’t raise the share price. If there’s nothing real to say, why force yourself to invent something to announce?
Juho is also being criticized in your posts for talking too much about partnering or possible future arrangements, while at the same time you’re demanding more announcements? Aren’t those a bit contradictory?
Patience! Faron has a promising drug candidate, and work is constantly being done to move it toward a finished drug. One step at a time. BEX won’t turn into a finished drug just because of shareholder demands!